Significance and Impact of Study: With increasing reports of bacterial resistance to antibiotics and the lack of new antibiotics being produced, bacteriophage therapy is becoming an attractive alternative. There has been no published report on the quality assurance of bacteriophage product to date. This is the first study on the quality assurance of a Ps. aeruginosa phage cocktail following pharmacopoeial requirements. The presence of bacterial endotoxin was found to be the key stumbling block for meeting regulatory criteria.
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Abstract
The aim of this study was to determine the stability and purity of a phage cocktail to be delivered by nebulisation. A cocktail of three phages active against Pseudomonas aeruginosa isolates from cystic fibrosis patients was developed for a potential nebulised formulation. The individual phages were examined for their retention of activity over time, while the phage cocktail was analysed for bacterial contaminant and endotoxin level according to regulatory requirements for nebulised products. The phage cocktail was nebulised using a Porta-neb nebuliser connected to an Anderson cascade impactor. The three phages retained activity over a period of 180 days storage at room temperature and at 4°C. Nebulised phages were recovered in the lower stages of the cascade impactor indicative of potential delivery deep into the lungs. The phage cocktail met bacterial limits but the endotoxin levels measured with the Limulus amoebocyte lysate (LAL) test remained considerably in excess of acceptable levels even following purification. These findings suggest that nebulisation of phage is a viable delivery option; although there is a need for appropriate depyrogenation strategies to remove bacterial endotoxins from phage based preparations in order to meet regulatory requirements.
Introduction
With renewed interest in the use of phage to treat bacterial infection, attention is drawn to the production of phage formulations for clinical use and the regulatory requirements that such a product must satisfy. These requirements vary depending on the intended application and route of administration with topical applications requiring less stringent microbiological controls than, for example, intravenous injections (Anon., 2013a,b) . In this regard, many of the commercially produced phage products currently undergoing trials are of a topical nature (Wright et al., 2009) . There is currently a paucity of information on the quality of phage products for clinical applications. This paper aims to investigate the alignment of a prototype nebulised phage formulation with selected pharmacopoeial requirements.
Results and Discussion
The phage cocktail described in this study met the British Pharmacopoeial bacterial limit test for non-sterile manufactured products (Anon., 2013c). All phage cocktails showed an absence of microbial contamination according to pharmacopeial standards (data not shown). In addition, there was no significant The production of endotoxin from the lysis of the Ps. aeruginosa strains used here represents a major hurdle for the further development of non-topical phage products and notably for nebulised applications. When endotoxin levels were assessed using the Endosafe PTS LAL kinetic assay, the phage cocktail showed high levels of endotoxin (>5 Log 10 EU ml -1
; Table 1 ). Following purification via passage through the Endotrap system, there was a small drop in endotoxin levels (approximately 0.2 Log 10 EU ml -1 ) but this was not significant when compared to the "unpurified" phage cocktails (P=0.327). This level of endotoxin far exceeds the pharmacopeial required levels (<0.2 EU ml -1
) and as such would fail quality assurance. To note, because of the level of endotoxin present in the phage cocktail, the LAL assay used here required the dilution of samples that were above the detection threshold of the cartridge (1 EU ml -1
), requiring the extrapolation of endotoxin levels from a positive result. Furthermore, the activity assessment of both "purified" and "unpurified" phage preparations on the Bioscreen C analyser shows a small but not significant decrease (P≥0.05) in the level of activity of the phages at 8 and 20 h (Table 1) . This is most probably caused by the small but non-significant reduction (P=0.124) in the phage number following passage through the Endotrap system. Although the use of an overlay based propagation method has been used in the current investigation this would not be appropriate for large scale manufacture, due to the relatively low throughput.
The determination of endotoxin levels in phage preparations have previously only
been measured with the rabbit pyrogenicity assay (Merabishvili et al., 2009 ). In our study, the pharmacopeial "gold standard" LAL assay (Anon, 2013d,e) has been used to quantify endotoxin levels in both "non-purified" and "purified" phage cocktails demonstrating unacceptably high endotoxin levels. The LAL assay not only provides quantitative data with regards to the total endotoxin levels within samples, but also is more sensitive than animal models (Ong et al., 2006) . The purification of phage preparations with the Endotrap Blue system has previously been demonstrated to be effective at reducing endotoxin levels in phage preparations (Merabishvili et al., 2009 ). In the current investigation endotoxin levels were not significantly altered by passage through the Endotrap Blue system. The saturation of the column with the high level of endotoxin present in our sample could explain the overall low reduction in the endotoxin level,
although this possibility was not tested at the time of the experiment. For laboratory scale preparation, caesium chloride gradients and PEG precipitations have been demonstrated to purify phages (Gill and Hyman, 2010 ) although this may be impractical for manufacturing processes due to associated costs with large scale centrifugation and the requirement to know buoyant densities of phages particularly for caesium chloride gradients.
This investigation illustrated the range of microbial quality control matters that should be addressed in the formulation of phage based products, in particular the endotoxin levels within phage preparations. Although the nebulised phage cocktail was stable over a 6-month period showing no bacterial contamination, the level of endotoxin remained high. Reducing the endotoxin level is the limiting factor in this study, (practical and financial), to produce an appropriate nebulised phage product.
Materials and Methods

Preparation of bacterial and bacteriophage inocula
Ps. aeruginosa strain PAO1 (Cooper et al., 2011) was routinely cultured for 24 h in 10 ml of tryptone soya broth (TSB, Oxoid, UK) at 37 o C prior to use and standardised to contain between 1-5 x 10 8 CFU ml -1 by reference to optical density measurements at 600nm.
Phage cocktail preparation
Phage GL-1, GL-1 2.5 and LP-M 10 described by Cooper et al. (2011) were used.
Individual phage stock was prepared by using Ps. aeruginosa PAO1 as host using the classical agar overlay method (Adams, 1959) . In brief, 10µl of a bacterial suspension (approx. 10 8 CFU ml CaCl 2 . Phages were diluted 1:10 in PBS and enumerated using the overlay agar method as described above. Phages were harvested as described previously by Cooper et al. (2011) . A cocktail containing equal amounts of phage GL-1, GL-1 2.5
and LP-M 10 (approx. 10 11 PFU ml 
Removal of endotoxins from the phage cocktail
Endotoxins were removed from the phage cocktail preparation using the Endotrap Blue Chromatography system (Hyglos, Germany) as follows: the prepacked column was drained and regenerated using the regeneration buffer . The phage suspension was then nebulised for 10 min after which the remaining phages in the Ventstream drug chamber were recovered and enumerated by the agar overlay method (Cooper et al., 2011) using Ps.
aeruginosa PAO1 as a host.
Steel sampling plates from each impactor stage were removed aseptically from the cascade impactor and transferred to sterile petri dishes. Ten ml sterile PBS was added to each petri dish, and the dishes shaken at 150 RPM for 15 min. The PBS wash fluid was then pipetted into a sterile centrifuge tube, vortexed and the phage enumerated by the agar overlay method (Cooper et al., 2011) using Ps.
Phage stability
Ps. aeruginosa phage suspensions of GL-1, GL-1 2.5 and LP-M 10 were prepared in phosphate buffered saline (PBS) using the agar overlay method (Cooper et al., 2011) . Following an initial quantification of phage viability, triplicate samples were stored at 4 ± 1 o C or room temperature (21 ± 1 o C). Phage viability was then measured by the agar overlay method using Ps. aeruginosa PAO1 as a host after 7, 30, 60, 90 and 180 days storage.
Endotoxin content
All glassware and containers were depyrogenated by dry heat sterilization at 
Determination of the bacterial content of the phage product
The level of microbial contamination in the phage cocktails before and after passaging through the Endotrap Blue Chromatography system was assessed in accordance with Pharmacopoeial requirements for non-sterile respiratory products (Anon. 2013c,g) as follows:
Total aerobic viable count: one ml of the phage cocktail was used to inoculate 20 ml of molten tryptone soya agar (TSA, Oxoid, UK) or 20 ml of Sabouraud dextrose agar (SAB; Oxoid, UK 
